Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Capital Expenditures (2022 - 2025)

Prokidney (PROK) has disclosed Capital Expenditures for 4 consecutive years, with $5.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures rose 116.18% to $5.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $35.0 million, a 527.3% increase, with the full-year FY2024 number at $29.5 million, down 13.71% from a year prior.
  • Capital Expenditures was $5.2 million for Q3 2025 at Prokidney, up from $3.1 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $27.9 million in Q3 2023 to a low of $306000.0 in Q4 2022.
  • A 4-year average of $5.0 million and a median of $1.1 million in 2025 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: soared 8769.52% in 2023, then tumbled 91.4% in 2024.
  • Prokidney's Capital Expenditures stood at $306000.0 in 2022, then surged by 413.73% to $1.6 million in 2023, then skyrocketed by 1522.71% to $25.5 million in 2024, then crashed by 79.63% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for PROK's Capital Expenditures are $5.2 million (Q3 2025), $3.1 million (Q2 2025), and $1.1 million (Q1 2025).